Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jiangsu Ocean Univ. σ1R compound 67: sourced facts only. name: "Among them, compound 67 demonstrated high binding affinity for both σ1R (Kᵢ = 8.8 nM) and H3R (KD = 31.2 nM)." [PMID:41616703]; target: "Among them, compound 67 demonstrated high binding affinity for both σ1R (Kᵢ = 8.8 nM) and H3R (KD = 31.2 nM)." [PMID:41616703]; developer: "Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, School of Pharmacy, Jiangsu Ocean University, Lianyungang, 222005, China." [PMID:41616703]; stage: "Compound 67 exhibited significant antinociceptive effects in the acetic acid-induced constriction test (ED50 = 0.18 mg/kg) and paclitaxel-induced neuropathic pain model (ED50 = 0.06 mg/kg), which demonstrated potency superior to that of marketed drug gabapentin." [PMID:41616703]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jiangsu Ocean Univ. σ1R compound 67.